Pembrolizumab-induced fulminant type 1 diabetes with c-peptide persistence at first referral

9Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

A 72-year-old man with no history of diabetes was referred to our department due to hyperglycemia during pembrolizumab treatment for non-small-cell lung carcinoma. His blood glucose level was 209 mg/dL, but he was not in a state of ketosis or ketoacidosis. Serum C-peptide levels persisted at first, but gradually decreased, and 18 days later, he was admitted to our hospital with diabetic ketoacidosis (DKA). The patient was diagnosed with fulminant type 1 diabetes (FT1D) induced by pembrolizumab. According to the literature, the insulin secretion capacity of a patient with type 1 diabetes (T1D) induced by anti-programmed cell death-1 (anti-PD-1) antibody is depleted in approximately 2 to 3 weeks, which is longer than that of typical FT1D. Patients with hyperglycemia and C-peptide persistence should be considered for hospitalization or frequent outpatient visits with insulin treatment because these could indicate the onset of life-threatening FT1D induced by anti-PD-1 antibodies. Based on the clinical course of this patient and the literature, we suggest monitoring anti-PD-1 antibody-related T1D.

Cite

CITATION STYLE

APA

Kusuki, K., Suzuki, S., & Mizuno, Y. (2020). Pembrolizumab-induced fulminant type 1 diabetes with c-peptide persistence at first referral. Endocrinology, Diabetes and Metabolism Case Reports, 2020(1), 1–5. https://doi.org/10.1530/EDM-19-0152

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free